Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt No Debt
GALT's Cash-to-Debt is ranked higher than
100% of the 815 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.12 vs. GALT: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
GALT' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.41  Med: No Debt Max: No Debt
Current: No Debt
Interest Coverage No Debt
GALT's Interest Coverage is ranked higher than
99% of the 638 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 118.48 vs. GALT: No Debt )
Ranked among companies with meaningful Interest Coverage only.
GALT' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Piotroski F-Score: 2
Altman Z-Score: -12.27
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
ROE % -211.99
GALT's ROE % is ranked lower than
97% of the 792 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.84 vs. GALT: -211.99 )
Ranked among companies with meaningful ROE % only.
GALT' s ROE % Range Over the Past 10 Years
Min: -1658.88  Med: -153.68 Max: -107.68
Current: -211.99
-1658.88
-107.68
ROA % -112.56
GALT's ROA % is ranked lower than
96% of the 821 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.58 vs. GALT: -112.56 )
Ranked among companies with meaningful ROA % only.
GALT' s ROA % Range Over the Past 10 Years
Min: -1309.12  Med: -143.39 Max: -71.42
Current: -112.56
-1309.12
-71.42
3-Year EBITDA Growth Rate 0.80
GALT's 3-Year EBITDA Growth Rate is ranked lower than
66% of the 606 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.20 vs. GALT: 0.80 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
GALT' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: -4.6 Max: 11.4
Current: 0.8
0
11.4
3-Year EPS without NRI Growth Rate -16.40
GALT's 3-Year EPS without NRI Growth Rate is ranked lower than
79% of the 580 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.90 vs. GALT: -16.40 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
GALT' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -33.7  Med: -5 Max: 36.2
Current: -16.4
-33.7
36.2
» GALT's 30-Y Financials

Financials (Next Earnings Date: 2017-08-09 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412    SIC: 2834
Compare:NAS:MEIP, OTCPK:BIOYF, NAS:ARLZ, OTCPK:ACNNF, OTCPK:EMMBF, NAS:LPCN, OTCPK:HYYDF, OTCPK:ICCLF, OTCPK:OWCP, NAS:TYHT, NAS:PSDV, OTCPK:WUYIF, OTCPK:SENZ, NAS:IMMY, OTCPK:GRMD, NAS:SPHS, OTCPK:CPHRF, NAS:AGRX, NAS:CPIX, NAS:JNP » details
Traded in other countries:PHPN.Germany,
Headquarter Location:USA
Galectin Therapeutics Inc is a clinical stage biopharmaceutical company. The Company is engaged in drug research and development to create new therapies for fibrotic disease and cancer.

Galectin Therapeutics Inc was incorporated in Nevada on January 26, 2001 as DTR-Med Pharma Corp. On May 10, 2001, DTR changed its name to Pro- Pharmaceuticals, Inc. On May 26, 2011, Pro-Pharmaceuticals, Inc. changed its name to Galectin Therapeutics Inc. Galectin Therapeutics is a development-stage company, which is engaged in drug development to create new therapies for cancer and fibrotic disease. The Company's drug candidates are based on its method of targeting galectin proteins, which are key mediators of biologic and pathologic function. The Company uses naturally occurring plant materials to create complex carbohydrates with specific molecular weights and pharmaceutical properties. The Company focuses on diseases with serious, life-threatening consequences to patients and those where current treatment options are limited. The Company has two compounds in development, one intended to be used in cancer therapy and the other intended to be used in the treatment of liver fibrosis and fatty liver disease. These two compounds are produced from completely different natural starting materials, both possessing the property which lends itself to binding to and inhibiting galectin proteins. GM-CT-01, its product candidate for cancer therapy, is a proprietary linear polysaccharide polymer comprised of mannose and galactose that has a precisely defined chemical structure and is derived from a plant source. GR-MD-02, its other product for treatment of liver fibrosis and fatty liver disease with inflammation and fibrosis, is a proprietary complex polysaccharide polymer possessing both linear and globular structures, which also is derived from a plant source. Its competitors include multinational pharmaceutical and chemical companies, specialized biotechnology firms and universities and other research institutions. The research, development, testing, manufacture, labeling, promotion, advertising, distribution, and marketing, among other things, of its products are extensively regulated by governmental authorities in the United States and other countries.

Top Ranked Articles about Galectin Therapeutics Inc

Patent for Reducing Inflammatory Response Granted to Galectin Therapeutics
Autoimmune Disease Patent Granted to Galectin Therapeutics
Galectin Therapeutics Reports 2017 First Quarter Financial Results and Provides Business Update
Charles Brandes Invests in Health Care in 1st Quarter Guru buys AstraZeneca, CVS, Gilead Sciences, others
Charles Brandes (Trades, Portfolio)’ Brandes Investment Partners gained 49 new holdings during the quarter. Among the purchases were several health care stocks. His three largest new health care holdings are AstraZeneca PLC (NYSE:AZN), CVS Health Corp. (NYSE:CVS) and Gilead Sciences Inc. (NASDAQ:GILD). Read more...
Galectin Therapeutics launches the Liver Line, an online community and publication on liver health and liver disease
Galectin Therapeutics Receives Notice of Japanese Decision to Grant a Composition of Matter Patent for GR-MD-02
Galectin Therapeutics and Exalenz to Present Late-Breaking Abstract at The International Liver Congress™ 2017
Galectin Therapeutics Reports 2016 Financial Results and Provides Business Update

NORCROSS, Ga., March 28, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results for the year ended December 31, 2016. These results are included in the Company’s Annual Report on Form 10-K, which has been filed with the U.S. Securities and Exchange Commission and is available at www.sec.gov.
Galectin Therapeutics management will host a conference call at 9:00 a.m. Eastern time March 28, 2017 to discuss this press release. To access the conference call dial 844-899-6544 and provide the operator with Pin Number 89964111. Galectin also invites all interested parties to listen to its conference call via webcast at http://edge.media-server.com/m/p/exukm2jh. The webcast will also be available on the investor relations portion of the Company’s website at http://galectintherapeutics.com/. The webcast will be archived on the Company’s website within two hours of the live call. The webcast will be available on the Company’s website at www.galectintherapeutics.com for 90 days. Management Commentary
“Galectin Therapeutics achieved a number of significant milestones in the development of our lead compound, GR-MD-02, during 2016,” said Peter G. Traber, M.D., president, chief executive officer and chief medical officer of Galectin Therapeutics. “Furthermore, we’ve recently completed equity financings that have generated sufficient funding to cover currently planned expenditures through 2017. "While non-alcoholic steatohepatitis (NASH) cirrhosis remains GR-MD-02’s primary disease target, a number of additional trials have provided encouraging early results that provide additional insight on the clinical effect of GR-MD-02.  In total, what we have seen in our early trials in moderate-to-severe plaque psoriasis and severe atopic dermatitis have consistently shown that GR-MD-02 demonstrates clinically significant, biological activity in humans. “NASH cirrhosis represents a large unmet medical need with no currently approved therapies, and we are very pleased with our progress in the NASH-CX trial. A drug that can halt progression of, or reverse existing fibrosis, in NASH cirrhosis patients would be a breakthrough therapeutic intervention that may prevent complications, alleviate the need for liver transplant, and even prevent death. “Our Phase 2b NASH-CX clinical trial enrollment exceeded its target and, to date, 71 patients have completed all 52 weeks of infusions with GR-MD-02, and 155 patients have completed 26 weeks of infusions. More than 3,400 infusions (or 85% of the maximum infusions in the trial) have been administered, with no drug-related serious adverse reactions and a dropout rate that is below the rate included in the trial design.  The top-line data readout of the NASH-CX trial remains on track for early December 2017. “The Providence Cancer Center is continuing two investigator-initiated Phase 1 clinical trials of GR-MD-02 used in combination with approved immunotherapies, Yervoy® and Keytruda® in patients with advanced melanoma, oral/head and neck cancer (OHN) and non-small cell lung cancer (NSCLC). There have been no safety concerns in either of these studies. Of the five patients with advanced melanoma who underwent combination therapy with GR-MD-02 (2 mg/kg) and Keytruda®, one had an impressive partial response, heading towards a complete response, and one had a mixed response. “Galectin Therapeutics also announced positive results in studies of GR-MD-02 for patients with serious skin diseases. This is an encouraging new indication for GR-MD-02 and one of the previously mentioned demonstrations that the drug is biologically active in humans. “A Phase 2, exploratory study of GR-MD-02 in patients with severe plaque psoriasis showed all five patients enrolled had significant clinical improvement (mean of 52% improvement) as measured by an objective measurement, the PASI (Psoriasis Area and Severity Index). After receiving 8 mg/kg doses of GR-MD-02 for up to 24 weeks, the fifth patient, who also had the most severe baseline disease, had an 82% PASI improvement approximately one month following the full thirteen infusions (24 weeks). “In an investigator-initiated protocol, GR-MD-02 was also used to treat three adult patients with severe atopic dermatitis, each of whom had been recalcitrant to multiple therapies over many years. All three patients have had a marked clinical effect with near resolution of pruritus, or itching, and regression of skin lesions.  Two patients achieved a 64% and 74% reduction in Eczema Area and Severity Index (EASI), after only 6 weeks and 3 drug infusions.  These findings are believed to demonstrate a clinically significant effect of this novel investigational drug in this patient population.” “In summary, we believe that Galectin is in a solid position from clinical, financial and leadership perspectives,” Dr. Traber concluded. Financial Results For the year ended December 31, 2016, the Company reported a net loss applicable to common stockholders of $22.4 million, or $0.76 per share, compared with a net loss applicable to common stockholders of $21.1 million, or $0.88 per share, for 2015.  The increase is largely due to higher research and development expenses primarily related to the Phase 2 clinical program. Research and development expense for 2016 was $15.3 million, compared with $13.1 million for 2015.  The increase primarily relates to costs for the Phase 2 clinical trials begun in 2015, partially offset by lower preclinical costs. General and administrative expense for 2016 was $6.2 million, compared with $7.0 million for 2015, primarily due to a decrease in stock based compensation. As of December 31, 2016, the Company had $15.4 million of non-restricted cash and cash equivalents. In January and February 2017, the Company raised a total of $1.5 million in net proceeds from issuance of common stock.   The Company believes it has sufficient cash to fund currently planned operations and research and development activities through December 31, 2017. About Galectin Therapeutics
Galectin Therapeutics is dedicated to developing novel therapies to improve the lives of patients with chronic liver and skin diseases and cancer. Galectin's lead drug (GR-MD-02) is a carbohydrate-based drug that inhibits the galectin-3 protein which is directly involved in multiple inflammatory, fibrotic, and malignant diseases. The lead development program is in non-alcoholic steatohepatitis (NASH) with cirrhosis, the most advanced form of NASH related fibrosis. This is the most common liver disease and one of the largest drug development opportunities available today. Additional development programs are in treatment of severe atopic dermatitis, moderate-to-severe plaque psoriasis, and in combination immunotherapy for advanced melanoma and other malignancies. Galectin seeks to leverage extensive scientific and development expertise as well as established relationships with external sources to achieve cost-effective and efficient development. Additional information is available at www.galectintherapeutics.com. Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or future financial performance, and use words such as “may,” “estimate,” “could,” “expect” and others. They are based on management’s current expectations and are subject to factors and uncertainties that could cause actual results to differ materially from those described in the statements. These statements include those regarding the hope that Galectin’s development program for GR-MD-02 will lead to the first therapy for the treatment of fatty liver disease with cirrhosis and those regarding the hope that our lead compounds will be successful in connection with cancer immunotherapy. Factors that could cause actual performance to differ materially from those discussed in the forward-looking statements include, among others, that Galectin may not be successful in developing effective treatments and/or obtaining the requisite approvals for the use of GR-MD-02 or any of its other drugs in development; the Company’s current clinical trial and any future clinical studies may not produce positive results in a timely fashion, if at all, and could prove time consuming and costly; plans regarding development, approval and marketing of any of Galectin’s drugs are subject to change at any time based on the changing needs of the Company as determined by management and regulatory agencies; regardless of the results of any of its development programs, Galectin may be unsuccessful in developing partnerships with other companies or raising additional capital that would allow it to further develop and/or fund any studies or trials.  Galectin has incurred operating losses since inception, and its ability to successfully develop and market drugs may be impacted by its ability to manage costs and finance continuing operations. For a discussion of additional factors impacting Galectin’s business, see the Company’s Annual Report on Form 10-K for the year ended December 31, 2016, and subsequent filings with the SEC. You should not place undue reliance on forward-looking statements. Although subsequent events may cause its views to change, management disclaims any obligation to update forward-looking statements. Galectin Therapeutics and its associated logo is a registered trademark of Galectin Therapeutics Inc. Yervoy® is a registered trademark of Bristol-Myers Squibb Keytruda® is a registered trademark of Merck & Co.  Condensed Consolidated Statements of Operations     Year Ended 
December 31,   2016   2015   (in thousands, except per share data)Operating expenses:       Research and development $15,325  $13,114 General and administrative  6,156   6,965 Total operating expenses  21,481   20,079 Total operating loss  (21,481)  (20,079)Other income:   Interest and other  45   52 Total other income  45   52 Net loss $(21,436) $(20,027)Preferred stock dividends and accretion costs  (914)  (1,097)Net loss applicable to common stock $(22,350) $(21,124)Basic and diluted net loss per share $(0.76) $(0.88)Shares used in computing basic and diluted net loss per share  29,216   24,120 
Condensed Consolidated Balance Sheet Data              December 31,
2016    December 31,
2015    (in thousands)Cash and cash equivalents  $15,362   $25,846Total assets   15,795    26,408Total current liabilities   3,780    1,360Total liabilities   3,780    1,360Total redeemable, convertible preferred stock   1,723    7,008Total stockholders’ equity  $10,292   $18,040

Contacts:
Jack Callicutt, Chief Financial Officer
(678) 620-3186
[email protected]

Read more...
Galectin Therapeutics Issues Statement Regarding GALTW and GALTU

NORCROSS, Ga., March 23, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announced today that trading will be halted in GALTW and GALTU at close of business on March 23, 2017 due to the expiration, on March 28, 2017, of certain publicly traded warrants that were issued in March 2012. The Company’s common stock, GALT, will not be affected and will continue to trade on the Nasdaq market. GALTU are units that were sold in March 2012 that consist of two shares of GALT common stock and one warrant.   Unit holders had the right at any time to separate each GALTU unit into two shares of GALT common stock and one publicly traded warrant, and most unit holders exercised that right.  GALTW are the free-standing warrants that were separated from the units. Unit holders who did not previously separate their units may now exchange each unit for two shares of GALT common stock.
About Galectin Therapeutics Galectin Therapeutics is dedicated to developing novel therapies to improve the lives of patients with chronic liver and skin diseases and cancer. Galectin's lead drug (GR-MD-02) is a carbohydrate-based drug that inhibits the galectin-3 protein which is directly involved in multiple inflammatory, fibrotic, and malignant diseases. The lead development program is in non-alcoholic steatohepatitis (NASH) with cirrhosis, the most advanced form of NASH related fibrosis. This is the most common liver disease and one of the largest drug development opportunities available today. Additional development programs are in treatment of severe atopic dermatitis, moderate-to-severe plaque psoriasis, and in combination immunotherapy for advanced melanoma and other malignancies. Galectin seeks to leverage extensive scientific and development expertise as well as established relationships with external sources to achieve cost-effective and efficient development.  Additional information is available at www.galectintherapeutics.com.
Contact:
Jack Callicutt, Chief Financial Officer
(678) 620-3186
[email protected]

Read more...
Galectin Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Business Update

NORCROSS, Ga., March 21, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announced today that the Company will release fourth quarter and full year 2016 results before the market opens on Tuesday, March 28, 2017. A copy of the earnings release will be available on the investor relations portion of the Company’s website at: http://galectintherapeutics.com/.
Management will provide a business update and conduct a question and answer session via a conference call beginning at 9:00 a.m. ET, Tuesday, March 28, 2017. To access the conference call dial 844-899-6544 and provide the operator with Pin Number 89964111. Galectin also invites all interested parties to listen to its conference call via webcast at http://edge.media-server.com/m/p/exukm2jh. The webcast will also be available on the investor relations portion of the Company’s website at http://galectintherapeutics.com/. The webcast will be archived on the Company’s website within two hours of the live call. About Galectin Therapeutics Galectin Therapeutics is dedicated to developing novel therapies to improve the lives of patients with chronic liver and skin diseases and cancer. Galectin's lead drug (GR-MD-02) is a carbohydrate-based drug that inhibits the galectin-3 protein which is directly involved in multiple inflammatory, fibrotic, and malignant diseases. The lead development program is in non-alcoholic steatohepatitis (NASH) with cirrhosis, the most advanced form of NASH related fibrosis. This is the most common liver disease and one of the largest drug development opportunities available today. Additional development programs are in treatment of severe atopic dermatitis, moderate-to-severe plaque psoriasis, and in combination immunotherapy for advanced melanoma and other malignancies. Galectin seeks to leverage extensive scientific and development expertise as well as established relationships with external sources to achieve cost-effective and efficient development.  Additional information is available at www.galectintherapeutics.com.
Contact:
Jack Callicutt, Chief Financial Officer
(678) 620-3186
[email protected]

Read more...

Ratios

vs
industry
vs
history
PB Ratio 128.00
GALT's PB Ratio is ranked lower than
99% of the 761 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.88 vs. GALT: 128.00 )
Ranked among companies with meaningful PB Ratio only.
GALT' s PB Ratio Range Over the Past 10 Years
Min: 0  Med: 0 Max: 457.5
Current: 128
0
457.5
Current Ratio 3.21
GALT's Current Ratio is ranked higher than
61% of the 795 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.40 vs. GALT: 3.21 )
Ranked among companies with meaningful Current Ratio only.
GALT' s Current Ratio Range Over the Past 10 Years
Min: 0.2  Med: 4.06 Max: 23.21
Current: 3.21
0.2
23.21
Quick Ratio 3.21
GALT's Quick Ratio is ranked higher than
70% of the 795 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.84 vs. GALT: 3.21 )
Ranked among companies with meaningful Quick Ratio only.
GALT' s Quick Ratio Range Over the Past 10 Years
Min: 0.2  Med: 4.06 Max: 23.21
Current: 3.21
0.2
23.21

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -20.50
GALT's 3-Year Average Share Buyback Ratio is ranked lower than
83% of the 477 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.30 vs. GALT: -20.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
GALT' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -26.1  Med: -19.9 Max: -10.6
Current: -20.5
-26.1
-10.6

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 11.50
GALT's Price-to-Net-Cash is ranked higher than
51% of the 243 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 11.42 vs. GALT: 11.50 )
Ranked among companies with meaningful Price-to-Net-Cash only.
GALT' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 2.69  Med: 12.07 Max: 210
Current: 11.5
2.69
210
Price-to-Net-Current-Asset-Value 126.50
GALT's Price-to-Net-Current-Asset-Value is ranked lower than
97% of the 521 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.35 vs. GALT: 126.50 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
GALT' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.69  Med: 12.4 Max: 732
Current: 126.5
2.69
732
Price-to-Tangible-Book 128.00
GALT's Price-to-Tangible-Book is ranked lower than
99% of the 701 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.54 vs. GALT: 128.00 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
GALT' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 2.71  Med: 12.3 Max: 430
Current: 128
2.71
430
Earnings Yield (Greenblatt) % -23.83
GALT's Earnings Yield (Greenblatt) % is ranked lower than
91% of the 820 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.97 vs. GALT: -23.83 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
GALT' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -25770.33  Med: 0 Max: 4520.18
Current: -23.83
-25770.33
4520.18

More Statistics

EPS (TTM) $ -0.66
Beta3.47
Short Percentage of Float5.91%
52-Week Range $0.49 - 3.68
Shares Outstanding (Mil)34.67

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $)
EPS ($) -0.40 -0.62 -0.87
EPS without NRI ($) -0.40 -0.62 -0.87
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for GALT

Headlines

Articles On GuruFocus.com
Patent for Reducing Inflammatory Response Granted to Galectin Therapeutics Jun 21 2017 
Autoimmune Disease Patent Granted to Galectin Therapeutics Jun 06 2017 
Galectin Therapeutics Reports 2017 First Quarter Financial Results and Provides Business Update May 15 2017 
Charles Brandes Invests in Health Care in 1st Quarter May 11 2017 
Galectin Therapeutics launches the Liver Line, an online community and publication on liver health a May 03 2017 
Galectin Therapeutics Receives Notice of Japanese Decision to Grant a Composition of Matter Patent f Apr 25 2017 
Galectin Therapeutics and Exalenz to Present Late-Breaking Abstract at The International Liver Congr Apr 18 2017 
Galectin Therapeutics Reports 2016 Financial Results and Provides Business Update Mar 28 2017 
Galectin Therapeutics Issues Statement Regarding GALTW and GALTU Mar 23 2017 
Galectin Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Busin Mar 21 2017 

More From Other Websites
[$$] Drug Companies Seek to Raise Awareness of Liver Ailment Jun 23 2017
Patent for Reducing Inflammatory Response Granted to Galectin Therapeutics Jun 21 2017
Galectin Therapeutics Announces Important Milestones towards Completion of NASH CX Trial Jun 13 2017
Autoimmune Disease Patent Granted to Galectin Therapeutics Jun 06 2017
Galectin Therapeutics Reports 2017 First Quarter Financial Results and Provides Business Update May 15 2017
Galectin Therapeutics launches the Liver Line, an online community and publication on liver health... May 03 2017
Can The Uptrend Continue for Galectin Therapeutics (GALT)? Apr 28 2017
Galectin Therapeutics Receives Notice of Japanese Decision to Grant a Composition of Matter Patent... Apr 25 2017
Will Henry Schein (HSIC) Deliver a Surprise in Q1 Earnings? Apr 24 2017
Can Myriad Genetics (MYGN) Spring a Surprise in Q3 Earnings? Apr 24 2017
Edward Lifesciences (EW) Q1 Earnings: A Surprise in Store? Apr 20 2017
Can Mead Johnson (MJN) Spring a Surprise in Q1 Earnings? Apr 20 2017
ResMed (RMD) Q3 Earnings: Disappointment in the Cards? Apr 18 2017
IDEXX Laboratories (IDXX) Q1 Earnings: Surprise in Store? Apr 18 2017
Galectin Therapeutics and Exalenz to Present Late-Breaking Abstract at The International Liver... Apr 18 2017
Can Illumina (ILMN) Spring a Surprise this Earnings Season? Apr 17 2017
5 Drug Stocks That Could Be Big Winners this Earnings Season Apr 17 2017
Integra LifeSciences (IART) Q1 Earnings: A Beat in Store? Apr 13 2017
GNC Holdings (GNC) Q1 Earnings: Disappointment in Store? Apr 12 2017
Galectin Therapeutics and Axovant Sciences See Stocks Rise on Investor Optimism Apr 11 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}